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Background: Generally, sentinel lymph node biopsy (SLNB) is performed in patients with clinically negative axillary
lymph node (LN). This study was to assess imaging techniques in axillary LN staging and to evaluate the feasibility
of SLNB in patients clinically suspected of axillary LN metastasis on preoperative imaging techniques (SI).
Methods: A prospectively maintained database of 767 breast cancer patients enrolled between January 2006 and
December 2009 was reviewed. All patients were offered preoperative breast ultrasound, magnetic resonance imaging,
and positron emission tomography scanning. SI patients were regarded as those for whom preoperative imaging was
“suspicious for axillary LN metastasis” and NSI as “non-suspicious for axillary LN metastasis” on preoperative imaging
techniques. Patients were subgrouped by presence of SI and types of axillary operation, and analyzed.
Results: For 323 patients who received SLNB, there was no statistically significant difference in axillary recurrence
(P=0.119) between SI and NSI groups. There also was no significant difference in axillary recurrence between SLNB and
axillary lymph node dissection (ALND) groups in 356 SI patients (P=0.420). The presence of axillary LN metastasis on
preoperative imaging carried 82.1% sensitivity and 45.9% specificity for determining axillary LN metastasis on the final
pathology.
Conclusions: SLNB in SI patents is safe and feasible. Complications might be avoided by not performing ALND.
Therefore, we recommend SLNB, instead of a direct ALND, even in SI patients, for interpreting the exact nodal status
and avoiding unnecessary morbidity by performing ALND.
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Sentinel lymph node biopsy (SLNB) is the preferred
method to assess the pathologic status of the axillary
lymph nodes (LNs) for patients with stage I or II breast
cancer [1-8]. SLNB has been recommended based on
the results of recent randomized clinical trials showing
decreased arm and shoulder morbidity in patients with
breast cancer undergoing SLNB compared with those
undergoing standard axillary lymph node dissection* Correspondence: bjsong@catholic.ac.kr
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reproduction in any medium, provided the or(ALND) [5,9]. However, not all patients are candidates
for SLNB.
According to the National Comprehensive Cancer
Network (NCCN) guideline, SLNB should be performed
in patients with clinically negative axillary LNs [10]. Yet,
SLNB is still not recommended by the American Society
of Clinical Oncology (ASCO) for large or locally ad-
vanced invasive breast cancers (T3 and T4), inflamma-
tory breast cancer, during pregnancy, in the setting of
prior non-oncologic breast surgery or axillary surgery,
and in the presence of suspicious palpable axillary LN.
In the ASCO guideline recommendations, the sensitivity
of SLN biopsy for node involvement ranged from 71% totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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69 studies (10,454 patients) analyzed [1]. Nevertheless,
the role of SLNB is increasing and even palpable axillary
LN alone is no longer a contraindication [11].
In the era of SLNB, the exclusion of LN metastases
using noninvasive methods could reduce the rate of
axillary surgery [12]. However, the experience of the
examiner is important for the diagnostic precision and
prediction. Therefore, the accuracy of the imaging study
has appropriately been questioned. It is well known that
sensitivity and positive predictive value of preoperative
axillary ultrasound (US) are low [13] and those of the
positron emission tomography (PET) scan are even
lower [14].
The aim of this study was to assess the imaging
techniques in axillary LN staging and to evaluate the
feasibility of SLNB even in patients clinically suspected




Between January 2006 and December 2009, 767 con-
secutive patients with biopsy-proven invasive breast
cancer were successfully treated by two breast surgeons.
All the patients were offered preoperative imaging tech-
niques including breast US, contrast-enhanced magnetic
resonance imaging (MRI), and PET scanning. Preopera-
tive MRI was done to determine the extent of surgery
(for example, wide excision or simple mastectomy).
PET-CT was performed to find out whether any distant
metastasis existed before the operation. Along with
mammography and ultrasound, these are routine pre-
operative examinations in our hospital. All clinical and
pathologic features were collected prospectively from
the database of Seoul St Mary’s Hospital.
Exclusion criteria were male gender, previous breast
cancer surgery, prior breast irradiation, known distant
metastasis, prior axillary surgery, inflammatory breast
cancer, and neoadjuvant chemotherapy. In the remaining
571 patients, SLN biopsy or ALND was performed.
Before May 2008, patients with clinically suspicious
axillary LN were treated with ALND. Consequently, 323
patients underwent SLNB and the remainder (n=248)
ALND. All protocols were approved by the institutional
review committee of the Seoul St Mary’s Hospital
(KC12RISI0396) and met the guidelines of the respon-
sible governmental agency.
Detection and false negative rate
SI patients were regarded as those for whom any of
preoperative imaging techniques (that is, US, MRI, and
PET scan) proved suspicious for axillary LN metastasis.
The detection rate was determined based on patientswho underwent successful SLNB and did not experience
conversion to ALND. Unscheduled ALND due to un-
successful SLNB was considered a failure and was used
to determine the failure rate. Axillary recurrence after
surgery represented a false negative and was used to
determine the false negative rate.
Imaging protocols
Axillary US was done by two experienced breast radiolo-
gists using a Seimens SEQUOIA 512 (Acuson, Mountain
View, CA, USA) equipped with a broad-band linear
probe (5 to 12 MHz). As in a recent study [15], axillary
LN was classified on the basis of cortical thickness
(cutoff 2.5 mm) and the appearance (for example, an
irregular nodular cortex, a diminished or absent fatty
hilum, or cortical thickening greater than 3 mm) on ultra-
sound for predicting the presence of axillary metastasis.
MRI was performed with a 1.5 tesla signa (GE Medical
Systems, Milwaukee, WI, USA) with fat-suppressed fast
spin-echo T2-weighted imaging (TR/TE=4000/85, flip
angle 90 degrees, 30 slices with field of view (FOV) of 240
mm, matrix 256 × 224, two NEX and 3 mm section
thickness with 0.1 mm intersection gap, acquisition time
2 minutes, 56 sec) and interpreted by two breast radiolo-
gists. PET-CT scanning (Biography LSO; Siemens Medical
Solutions, Knoxville, TN, USA) was performed after 8
hours of fasting. Patients were injected intravenously with
12.5 mCi of 2-(fluorine-18)-fluoro-deoxy-D-glucose (F-18
FDG) in the contralateral hand. One hour after injection,
patients were positioned in the scanner with their arms
above their heads. Attenuation correction of images
was not performed. A single nuclear physician who was
aware of the diagnosis of breast carcinoma interpreted
the scans.
Sentinel lymph node biopsy
Before 2010, SLNB was performed using the blue dye
method in our hospital because we had no isotope or
gamma probe before the year 2010; we used a standard
1-day protocol using the blue dye for localization.
Briefly, at the operation, 4 ml of 0.8% Indigocarmine
Blue dye (Carmine; Korea United Pharm., Seomyoen,
Chungnam, South Korea) was used. Injections were
given subdermally into the upper and outer areolar
borders. If a node was blue or suspicious, it was consi-
dered a sentinel lymph node (SLN). A 5-cm incision
along the anteroinferior border or the axillary hairline
was done and SLNs were retrieved manually and sent
for frozen section analysis.
Histologic evaluation
SLNs or nodes were sliced at approximately 2-mm inter-
vals along the longitudinal axis of the LN. The largest
slice from each SLN was subjected to immediate frozen-
Table 1 Clinical and pathologic characteristics of 571
patients
Characteristics SLNB(n=323) ALND(n=248) P(Chi-square test)


















Stage I 199 87
Stage IIA 78 94
Stage IIB 29 40
Stage IIIA 10 16
Stage IIIB 0 2
Stage IIIC 7 9
Size of tumor, cm,
mean ± SD


























SLNB, sentinel lymph node biopsy; ALND; axillary lymph node dissection; ER,
estrogen receptor; PR,progesterone receptor; IHC,immunohistochemistry.
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staining and standard evaluation was assessed for the
presence of metastases by an experienced breast
pathologist. If a frozen section confirmed the presence
of metastases in the SLN, completion ALND was done.
The remaining tissue of the axillary SLNs was fixed in
formalin and embedded in paraffin for the permanent
pathologic report. The pathologist assessed lymph nodes
with H&E staining only. When the final diagnosis of
axillary LN metastasis was made, we performed addi-
tional ALND. All of patients with axillary LN metastasis
underwent adjuvant chemotherapy.
Estrogen receptor, progesterone receptor, and HER2
status
Estrogen receptor (ER), progesterone receptor (PR) and
HER2 status was reviewed from medical records.
Hormone receptor status was determined using an en-
zyme immunoassay and reported in the medical records
between 2006 and 2009. The receptor status had been
determined using a commercial enzyme immunoassay
according to the instructions of the manufacturer
(Abbott Laboratories, Chicago, IL, USA). A result ex-
ceeding 15 fmol/mg was considered positive for the
presence of the particular receptor. Tissue microarray
(TMA) of primary breast tissue was used for analysis of
HER2 overexpression. Immunohistochemistry (IHC) or
fluorescence in situ hybridization (FISH) for evaluating
HER2 status was performed, and an IHC score of three
positive or FISH-positive was defined as positive for
HER2 overexpression. The IHC method was briefly as
follows; five-micrometer sections of paraffin-embedded
tissue arrays were deparaffinized, rehydrated in a graded
series of alcohol solutions and microwave-treated for 10
minutes in a pH 6.0 citrate buffer. The endogenous
peroxidase activity was blocked using 0.3% hydrogen
peroxide. The tissue arrays were processed in an auto-
matic IHC staining machine using standard procedures
(Lab Vision autostainer; Lab Vision, Fremont, CA, USA)
and a ChemMate™ EnVision™ system (DAKO, Carpinteria,
Table 2 Clinical and pathologic characteristics of SLNB for

























Stage I 101 98
Stage IIA 37 41
Stage IIB 8 21
Stage IIIA 1 9
Stage IIIC 0 7
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*Clinically suspicious for axillary LN metastasis on preoperative imaging
techniques (SI) patients are those with any of preoperative imaging
techniques, including US, MRI, and PET scan, who were suspected of axillary
LN metastasis, and NSI are those not suspected of LN metastasis.ER,estrogen
receptor; PR,progesterone receptor; IHC,immunohistochemistry.
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HER2/CEN probe (Vysis, Downers Grove, IL, USA). The
c-erbB2 to chromosome 17 centromere ratio was mea-
sured in at least 60 nuclei from the tumor cells, and an
average score was taken. More than two copies of c-erbB2
for each chromosome 17 were considered to be a positive
sign for c-erbB2 gene amplification.
Statistical analyses
The primary endpoint was axillary recurrence. Adjuvant
therapy comprising chemotherapy and/or radiotherapy
was performed for all the patients who underwent an
operation according to the standard protocols used in
our hospital. Axillary recurrence-free survival (ARFS)
was defined as the time from definitive breast surgery
to first documented axillary recurrence. The results
were presented as the mean ± SD or number (%) as
appropriate. The chi-square test was used to compare
categorical variables, and the independent two-sample
t-test was used to compare the values of continuous
variables between groups. The Kaplan-Meier method
was used for survival analysis and the log rank test
for estimating the axillary ARFS. All statistical tests
were two-sided, and a P-value < 0.05 was considered
statistically significant.
Results
One hundred ninety six patients were excluded, leav-
ing 571 patients for the study. Median follow up was
45 months (range, 1 to 73 months). Factors evaluated
for clinical and pathologic features were mean age of
the patients, axillary recurrence, recurrence, tumor
(T) and node (N) stage, pathologic stage, size of
tumor, nuclear and histologic grade, ER status, PR
status, IHC, and lymphovascular invasion. Axillary re-
currence occurred in 6 of 323 patients in the SLNB
group, and 10 of 248 patients in the ALND group
(Table 1).
Clinical and pathologic features for the 323 patients of
the SLNB group were studied and the results were
compared with those of patients who were clinically
non-suspicious for axillary LN metastasis (NSI) and SI.
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SI patient age was 51.90 and 50.35 years, respectively,
and was not significantly different between the two
groups (P=0.790). Axillary recurrence was noted more
frequently in the SI group but not with statistical signifi-
cance (1/147 vs 5/171, P=0.152). The sole factor associ-
ated with SI patients was recurrence. Other factors
associated with clinical suspicion of lymph node metas-
tasis on univariate analysis were T and N stage, patho-
logic stage, ER status, nuclear and histologic grade, and
lymphovascular invasion.
During the study period, five patients of the SLNB
group experienced failure because no sentinel nodes
were found during the operation. Therefore, the detec-
tion rate of SLN was 98.5% (318/323). The 5-year
axillary recurrence rate was 0.7% (1/147) for NSI
patients and 2.8% (5/176) for SI patients; the rates were
not statistically significant (P=0.295) Therefore, ARFS
was estimated as 97.2% (171/176) for SI and 99.3% (146/
147), respectively (Figure 1) and there was no statisti-
cally significant difference in the false negative rate.
Further statistical analyses were done for patients
clinically suspected of LN metastasis. The patients were
subgrouped as SLNB and ALND (Table 3). There was
no statistically significant difference in axillary recur-
rence between the two groups (5/176 vs 8/180, P=0.420)
and a Kaplan-Meier curve showed no difference
(P=0.486, Figure 2).Figure 1 Evaluation of axillary recurrence-free survival (ARFS) for sub
lymph node recurrence on preoperative imaging studies; NSI, clinically non
imaging studies.The presence of axillary LN metastasis on preoperative
imaging carried an 82.1% sensitivity, 45.9% specificity,
38.8% positive predictive value (PPV), and 86.1%
negative predictive value (NPV) for determining axillary
LN metastasis on final pathology. PET-CT was the most
sensitive imaging technique (62.41%) for identifying
axillary LN metastasis, followed by MRI (61.73%) and
US (59.88%) (Table 4). Specificity for the imaging
techniques was 82.96% for PET-CT, 82.09% for US, and
78.24% for MRI. The specificity of SI was low (45.9%)
and unnecessary ALND was performed in more than
half of the patients.
Discussion
The aim of this study was to determine whether it is safe
and feasible to perform SLNB in patients with clinically
suspicious axillary LN metastasis on preoperative
imaging studies. The disease status of the axillary LN is
the most significant prognostic factor for patients with
breast cancer [16]. SLNB is feasible and accurate, works
well in a wide range of practice settings, increases sta-
ging accuracy by allowing enhanced pathologic analysis,
has less morbidity than ALND, and gives local control
comparable to that of ALND [17]. Therefore, ALND for
uninvolved axillary LN is considered unnecessary and
improper, and indication of SLNB is important. Pres-
ently, there was no statistically significant difference in
axillary recurrence between SLNB and ALND groups forgroups based on imaging studies. SI, clinically suspicious axillary
-suspicious axillary lymph node recurrence on preoperative
Table 3 Clinical and pathologic characteristics of patients
clinically suspected of lymph node metastasis for

























Stage I 98 54
Stage IIA 41 63
Stage IIB 21 38
Stage IIIA 9 15
Stage IIIB 0 2
Stage IIIC 7 8
Size of tumor, cm,
mean ± SD















Table 3 Clinical and pathologic characteristics of patients
clinically suspected of lymph node metastasis for








ER,estrogen receptor; PR,progesterone receptor; IHC,immunohistochemistry.
Kwak et al. World Journal of Surgical Oncology 2013, 11:104 Page 6 of 8
http://www.wjso.com/content/11/1/104clinically suspicious axillary LN metastasis (P=0.420).
Therefore, SLNB in clinically suspicious patients on
preoperative imaging studies might be safe and feasible
in the clinical setting.
The NCCN guideline recommends that SLNB should
be performed in patients with clinically negative axillary
LNs [10]. Still, many authorities consider clinically
positive axillary LNs a contraindication for SLNB [1].
Nevertheless, the role of SLNB is increasing and various
studies have shown that clinical assessment of axillary
LNs alone is inaccurate with a false positive rate up to
40% [11,18]. In our study, SI patients were regarded as
those for whom the preoperative imaging techniques of
US, MRI, and PET-CT scanning revealed suspicion of
axillary LN. Owing to the low specificity of imaging
studies, direct ALND in SI patients could potentially
lead to unnecessary ALND.
This study emphasizes the feasibility of SLNB, even in
SI patients. More than 60% of all primary operable
breast cancers do not have axillary LN metastasis [12].
Non-invasive methods like US, MRI, PET-CT have
gained more importance in staging axillary LN. Never-
theless, no imaging study is completely accurate. Axillary
US provides additional value in detecting pathological
axillary LN [19,20] but sensitivity has reportedly varied
from 26.4% (15.3% to 40.3%) to 75.9% (56.4% to 89.7%)
and specificity from 88.4% (82.1% to 93.1%) to 98.1%
(90.1% to 99.9%) [21]. A meta-analysis of 25 studies
including 2,460 patients reported that PET-CT provided
lower sensitivity (37% to 85%) and high specificity (84%
to 100%) [22]. The present analysis also indicated that
the sensitivity of PET-CT is not sufficient for staging
axillary LNs. Also, adding axillary MRI sequentially after
axillary US does not significantly improve detection rate
of positive nodes [23]. In our study, 56.57% of accuracy
(Table 4) was shown with preoperative imaging
techniques and false positivity of SI reached 61.23%
(218/356) (Table 3). Hence, SLNB in SI patients might
be possible.
Figure 2 Evaluation of axillary recurrence-free survival (ARFS) for subgroups based on type of axillary operation. SLNB, sentinel lymph
node biopsy; ALND, axillary lymph node dissection.












US 59.88 82.09 58.14 83.12 75.57
MRI 61.73 78.24 54.35 82.97 73.36
PET-CT 62.41 82.96 65.67 80.87 75.91
SI* 82.14 45.91 38.76 86.05 56.57
*SI are patients in whom a preoperative imaging technique, including breast
ultrasound (US), contrast-enhanced magnetic resonance imaging (MRI), and
positron emission tomography (PET)-CT scanning, revealed suspected axillary
LN metastasis. PPV, positive predictive value; NPV, negative predictive value.
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spared an SLNB with the aid of preoperative axillary US
combined with fine-needle aspiration cytology (FNAC)
[24]. Indeed, when FNAC is combined, the likelihood
of false positives and false negatives would decrease
[13]. However, preoperative axillary US alone is insuffi-
ciently specific to obviate the need for SLNB because
of the substantial number of false negative results,
especially in stage N1 disease, although it may almost
exclude N2 and N3 disease [25]. In our study, 52/323
patients (16.1%) who underwent SLNB were proved to
have N1 disease. Therefore, preoperative axillary US
combined with FNAC alone might have produced
false negative results with additional costs. In fact, we tried
to perform routine axillary US combined with core needle
biopsy but a number of patients (the proportion is not
identifiable) refused to perform additional biopsy due to
additional pain, cost, and bleeding.
There are some limitations to our study. First, it is a
retrospective review of a small number of patients.
Further evaluation with a large number of prospective
randomized controlled studies must be done in a more
standardized group for validation. Second, there were
some confounding factors concerning postoperative
adjuvant therapies, including radiation, systemic, or
endocrine therapies. These factors could have
influenced the results. Despite these limitations, the
study is significant and is the first to recommend
SLNB in SI, based on its demonstrated feasibility and
safety.Our evaluation of SLNB in SI patients with breast
cancer suggests that no imaging techniques can re-
place surgical staging and histologic confirmation of
nodal status [14]. Hence the inaccuracy of the imaging
techniques allows indications of SLNB widening and
SLNB in SI patients is safe and feasible. However,
further prospective trials with a larger cohort of
patients with long-term follow up are required to ver-
ify this observation.Conclusions
The inaccuracy of the imaging techniques allows wide-
ning of indications of SLNB. Therefore, we recommend
SLNB, instead of a direct ALND, even in SI patients,
for interpreting the exact nodal status and avoiding
unnecessary morbidity by performing ALND.
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